HCV antibody + | HCV antibody − | OR (95% CI) | |
All | 1256 | 2410 | |
RPR reactive | 180 (14%) | 174 (7%) | 2.15 (1.7 to 2.7) |
BFP | 55 | 32 | |
Of all reactive RPR | (31%) | (19%) | 1.9 (1.1 to 3.1) |
Of all syphilis tests | (4%) | (1%) | 3.3 (2.1 to 5.1) |
No history of IDU | 378 | 2365 | |
RPR reactive | 58 (15%) | 163 (7%) | 2.5 (1.8 to 3.4) |
BFP | 14 | 31 | |
Of all reactive RPR | (24%) | (19%) | NS |
Of all syphilis tests | (4%) | (1%) | 3.1 (1.6 to 5.9) |
HIV seronegative | 185 | 748 | |
RPR reactive | 21 (11%) | 37 (5%) | 2.5 (1.4 to 4.3) |
BFP | 10 | 7 | |
Of all reactive RPR | (48%) | (19%) | 3.9 (1.0 to 15.2) |
Of all syphilis tests | (5%) | (1%) | 6.0 (2.1 to 15.0) |
HIV seronegative/no history of IDU | 48 | 692 | |
RPR reactive | 9 (19%) | 35 (5%) | 4.3 (2.0 to 9.7) |
BFP | 3 | 6 | |
Of all reactive RPR | (33%) | (17%) | NS |
Of all syphilis tests | (6%) | (1%) | 7.6 (1.9 to 12.5) |
BFP, biological false positive; HCV, hepatitis C virus; IDU, intravenous drug use; NTST, non-treponemal serological test; OR, odds ratio; RPR, rapid plasma reagin.